Wight Joel, Witkowski Tom, Keane Colm, Hawkes Eliza A
Austin Health Heidelberg Australia.
Olivia Newton-John Cancer Research Institute Victoria Australia.
EJHaem. 2025 Jul 8;6(4):e70097. doi: 10.1002/jha2.70097. eCollection 2025 Aug.
Tumour infiltrating lymphocyte (TIL) T-cell receptor (TCR) repertoire is prognostic in newly diagnosed diffuse large B-cell lymphoma (DLBCL), but evolution has not been evaluated at relapse.
We examined the TCR repertoire in nine paired DLBCL samples from diagnosis and relapse.
We noted considerable differences, with dominant clones at diagnosis replaced at relapse by new clones that were absent or minor initially. There was low linearity between diagnostic and relapsed samples (-values 0.01-0.316), with shared clones averaging 8.3% (range 0%-37%). Clonal diversity was reduced in relapsed samples, suggesting an increasingly defunct intratumoural immune response.
T-cell diversity is reduced in relapsed/refractory DLBCL, which may have implications for immunotherapy usage.
肿瘤浸润淋巴细胞（TIL）的T细胞受体（TCR）库对新诊断的弥漫性大B细胞淋巴瘤（DLBCL）具有预后价值，但复发时的演变情况尚未得到评估。
我们检测了9例DLBCL配对样本在诊断和复发时的TCR库。
我们注意到存在显著差异，诊断时的优势克隆在复发时被最初不存在或为少数的新克隆所取代。诊断样本与复发样本之间的线性关系较低（相关系数值为0.01 - 0.316），共享克隆平均为8.3%（范围为0% - 37%）。复发样本中的克隆多样性降低，提示肿瘤内免疫反应日益失效。
复发/难治性DLBCL中的T细胞多样性降低，这可能对免疫治疗的应用产生影响。
